Balyasny Asset Management
ABUS icon

Balyasny Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Balyasny Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$565K Sell
125,521
-16,125
-11% -$70.5K ﹤0.01% 2322
2025
Q4 		$681K Buy
141,646
+33,981
+32% +$153K ﹤0.01% 2373
2025
Q3 		$489K Buy
+107,665
New +$395K ﹤0.01% 2405
2025
Q2 		– Sell
-18,916
Closed -$66K – 2741
2025
Q1 		$66K Sell
18,916
-22,774
-55% -$75.9K ﹤0.01% 2703
2024
Q4 		$136K Buy
+41,690
New +$153K ﹤0.01% 2578
2023
Q1 		– Sell
-14,633
Closed -$34.1K – 2576
2022
Q4 		$34.1K Buy
14,633
+2,384
+19% +$5.7K ﹤0.01% 2404
2022
Q3 		$23K Buy
+12,249
New +$28.8K ﹤0.01% 2566
2021
Q2 		– Sell
-12,147
Closed -$40K – 1912
2021
Q1 		$40K Buy
+12,147
New +$46.9K ﹤0.01% 1689

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Balyasny Asset Management's ABUS Position: Q1 2026 in Review

Balyasny Asset Management reduced its Arbutus Biopharma (ABUS) stake by 11% in Q1 2026, selling an estimated $70.5K and leaving 125,521 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #2322.

Balyasny Asset Management first reported a position in ABUS in Q1 2021 and has held it in 8 quarters since. The position peaked at $681K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Balyasny Asset Management held 125,521 shares of Arbutus Biopharma worth $565K as of Q1 2026.
  • Balyasny Asset Management sold 16,125 Arbutus Biopharma shares in Q1 2026, an estimated $70.5K.
  • Arbutus Biopharma made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2322 holding.
  • Balyasny Asset Management first reported a position in Arbutus Biopharma in Q1 2021 and has held it in 8 quarters since.
  • Balyasny Asset Management's Arbutus Biopharma position peaked at $681K in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.